| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 69 | 2022 | 1484 | 9.080 |
Why?
|
| Vasoconstriction | 52 | 2022 | 592 | 8.110 |
Why?
|
| Matrix Metalloproteinases | 18 | 2021 | 392 | 6.790 |
Why?
|
| Vasodilation | 38 | 2021 | 964 | 6.650 |
Why?
|
| Uterus | 17 | 2024 | 651 | 4.160 |
Why?
|
| Matrix Metalloproteinase 2 | 13 | 2022 | 462 | 4.000 |
Why?
|
| Endothelium, Vascular | 37 | 2019 | 4437 | 3.960 |
Why?
|
| Matrix Metalloproteinase 9 | 12 | 2024 | 633 | 3.750 |
Why?
|
| Pre-Eclampsia | 19 | 2022 | 1230 | 3.680 |
Why?
|
| Hypertension, Pregnancy-Induced | 10 | 2024 | 517 | 3.580 |
Why?
|
| Placenta | 20 | 2024 | 1701 | 3.510 |
Why?
|
| Varicose Veins | 13 | 2020 | 155 | 3.480 |
Why?
|
| Vascular Diseases | 11 | 2022 | 1180 | 3.080 |
Why?
|
| Nitric Oxide | 31 | 2021 | 2141 | 3.040 |
Why?
|
| Hypertension | 38 | 2023 | 8595 | 2.990 |
Why?
|
| Uterine Artery | 4 | 2024 | 30 | 2.920 |
Why?
|
| Muscle Contraction | 26 | 2021 | 1201 | 2.780 |
Why?
|
| Vena Cava, Inferior | 11 | 2020 | 458 | 2.730 |
Why?
|
| Rats, Sprague-Dawley | 57 | 2024 | 8157 | 2.610 |
Why?
|
| Vasoconstrictor Agents | 30 | 2023 | 651 | 2.550 |
Why?
|
| Pregnancy, Animal | 11 | 2014 | 124 | 2.500 |
Why?
|
| Protein Kinase C | 24 | 2016 | 1201 | 2.460 |
Why?
|
| ADAM Proteins | 5 | 2022 | 240 | 2.390 |
Why?
|
| Calcium | 40 | 2016 | 5726 | 2.300 |
Why?
|
| Phenylephrine | 33 | 2016 | 293 | 2.070 |
Why?
|
| Cyclic GMP | 15 | 2017 | 395 | 2.040 |
Why?
|
| Estrogens | 13 | 2023 | 1520 | 2.000 |
Why?
|
| Pregnancy Complications, Cardiovascular | 11 | 2016 | 516 | 1.970 |
Why?
|
| Ischemia | 12 | 2024 | 1893 | 1.940 |
Why?
|
| Uterine Contraction | 4 | 2022 | 91 | 1.900 |
Why?
|
| Rats | 64 | 2024 | 23695 | 1.830 |
Why?
|
| Calcium Signaling | 11 | 2018 | 731 | 1.820 |
Why?
|
| Receptor, Endothelin B | 5 | 2014 | 46 | 1.820 |
Why?
|
| Disintegrins | 3 | 2022 | 27 | 1.680 |
Why?
|
| Blood Pressure | 32 | 2024 | 8523 | 1.680 |
Why?
|
| Biological Factors | 3 | 2023 | 158 | 1.660 |
Why?
|
| Progesterone | 10 | 2022 | 742 | 1.630 |
Why?
|
| Hypertension, Pulmonary | 6 | 2022 | 1570 | 1.500 |
Why?
|
| Receptors, Estrogen | 11 | 2013 | 2202 | 1.480 |
Why?
|
| Estrogen Receptor beta | 5 | 2015 | 168 | 1.450 |
Why?
|
| Blood Vessels | 9 | 2017 | 1112 | 1.430 |
Why?
|
| Caveolin 1 | 4 | 2015 | 257 | 1.420 |
Why?
|
| Aorta | 21 | 2017 | 2042 | 1.400 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2013 | 1207 | 1.380 |
Why?
|
| Gonadal Steroid Hormones | 8 | 2010 | 701 | 1.380 |
Why?
|
| Pregnancy | 56 | 2024 | 29725 | 1.380 |
Why?
|
| Neovascularization, Physiologic | 5 | 2021 | 1335 | 1.330 |
Why?
|
| Animals | 140 | 2024 | 167940 | 1.320 |
Why?
|
| Glycosaminoglycans | 3 | 2024 | 606 | 1.280 |
Why?
|
| Mesenteric Arteries | 5 | 2021 | 178 | 1.280 |
Why?
|
| Angiotensin II | 10 | 2023 | 850 | 1.180 |
Why?
|
| Microvessels | 4 | 2022 | 572 | 1.180 |
Why?
|
| Estrogen Receptor alpha | 5 | 2015 | 580 | 1.150 |
Why?
|
| Myometrium | 3 | 2022 | 176 | 1.140 |
Why?
|
| Potassium Chloride | 16 | 2013 | 233 | 1.130 |
Why?
|
| Pulmonary Artery | 6 | 2022 | 1919 | 1.120 |
Why?
|
| Venous Insufficiency | 3 | 2024 | 111 | 1.110 |
Why?
|
| Endothelin-1 | 7 | 2013 | 302 | 1.060 |
Why?
|
| Placental Circulation | 4 | 2021 | 37 | 1.060 |
Why?
|
| Estradiol | 12 | 2013 | 1932 | 1.060 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2022 | 685 | 1.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 16 | 2015 | 260 | 1.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 558 | 1.010 |
Why?
|
| Thrombospondins | 3 | 2022 | 193 | 1.010 |
Why?
|
| Nitric Oxide Synthase | 10 | 2015 | 908 | 1.000 |
Why?
|
| Adaptation, Physiological | 5 | 2016 | 1297 | 1.000 |
Why?
|
| Signal Transduction | 29 | 2020 | 23363 | 0.970 |
Why?
|
| Vasomotor System | 3 | 2016 | 207 | 0.970 |
Why?
|
| Vasodilator Agents | 14 | 2013 | 977 | 0.920 |
Why?
|
| Angiotensin I | 1 | 2023 | 56 | 0.910 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2011 | 293 | 0.890 |
Why?
|
| Biological Phenomena | 1 | 2023 | 28 | 0.880 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2017 | 151 | 0.860 |
Why?
|
| Enzyme Induction | 3 | 2013 | 452 | 0.820 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 704 | 0.820 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2024 | 142 | 0.790 |
Why?
|
| Menopause | 6 | 2012 | 1640 | 0.780 |
Why?
|
| Sodium, Dietary | 3 | 2015 | 425 | 0.760 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2020 | 1199 | 0.750 |
Why?
|
| Veins | 4 | 2015 | 765 | 0.740 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 4357 | 0.740 |
Why?
|
| Placentation | 2 | 2020 | 78 | 0.740 |
Why?
|
| Endothelins | 8 | 2014 | 127 | 0.730 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2021 | 91 | 0.730 |
Why?
|
| Receptor, Endothelin A | 3 | 2014 | 56 | 0.680 |
Why?
|
| Receptors, Endothelin | 3 | 2011 | 56 | 0.650 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2015 | 164 | 0.630 |
Why?
|
| Enzyme Inhibitors | 20 | 2015 | 3726 | 0.630 |
Why?
|
| Acetylcholine | 11 | 2012 | 629 | 0.610 |
Why?
|
| Arteries | 5 | 2015 | 1126 | 0.610 |
Why?
|
| Sodium Chloride | 4 | 2006 | 596 | 0.600 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2018 | 57 | 0.590 |
Why?
|
| Epoprostenol | 4 | 2012 | 248 | 0.580 |
Why?
|
| Muscle Relaxation | 4 | 2012 | 138 | 0.580 |
Why?
|
| Disease | 3 | 2017 | 671 | 0.580 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 3 | 2017 | 97 | 0.570 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1173 | 0.570 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2017 | 60 | 0.570 |
Why?
|
| Isoenzymes | 9 | 2005 | 1690 | 0.550 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2023 | 60 | 0.550 |
Why?
|
| Coronary Vasospasm | 5 | 2004 | 83 | 0.540 |
Why?
|
| Organ Specificity | 3 | 2017 | 1955 | 0.530 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 279 | 0.530 |
Why?
|
| Female | 84 | 2024 | 391011 | 0.530 |
Why?
|
| Calcium Channel Blockers | 7 | 2016 | 694 | 0.530 |
Why?
|
| Enzyme Assays | 1 | 2017 | 108 | 0.520 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 498 | 0.520 |
Why?
|
| Collagen | 3 | 2022 | 2635 | 0.520 |
Why?
|
| HELLP Syndrome | 1 | 2015 | 40 | 0.510 |
Why?
|
| Vascular Resistance | 6 | 2013 | 932 | 0.500 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 214 | 0.490 |
Why?
|
| Isometric Contraction | 7 | 2013 | 146 | 0.490 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2023 | 148 | 0.490 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2015 | 232 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10829 | 0.480 |
Why?
|
| Testosterone | 9 | 2023 | 2469 | 0.470 |
Why?
|
| Phytoestrogens | 2 | 2012 | 59 | 0.470 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 1746 | 0.470 |
Why?
|
| Intracellular Membranes | 3 | 2002 | 389 | 0.460 |
Why?
|
| Blood Circulation | 1 | 2015 | 249 | 0.460 |
Why?
|
| Sex Characteristics | 6 | 2023 | 2627 | 0.460 |
Why?
|
| Litter Size | 3 | 2021 | 49 | 0.460 |
Why?
|
| Collagen Type I | 1 | 2017 | 615 | 0.450 |
Why?
|
| Extracellular Matrix | 7 | 2020 | 1726 | 0.450 |
Why?
|
| Renal Artery | 3 | 2015 | 368 | 0.450 |
Why?
|
| Pancreatic Elastase | 2 | 2004 | 128 | 0.450 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18134 | 0.450 |
Why?
|
| Peptide Fragments | 3 | 2023 | 5120 | 0.440 |
Why?
|
| Placental Insufficiency | 2 | 2004 | 50 | 0.440 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 755 | 0.440 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 83 | 0.430 |
Why?
|
| Receptors, Epoprostenol | 1 | 2012 | 12 | 0.420 |
Why?
|
| Coronary Vessels | 7 | 2004 | 3112 | 0.410 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.410 |
Why?
|
| Protein Kinase C-epsilon | 3 | 2007 | 43 | 0.410 |
Why?
|
| Up-Regulation | 5 | 2017 | 4127 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 3483 | 0.410 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 11902 | 0.410 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2015 | 1244 | 0.400 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 15740 | 0.400 |
Why?
|
| Acidosis, Respiratory | 1 | 2012 | 38 | 0.400 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 36 | 0.400 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 309 | 0.390 |
Why?
|
| Venous Pressure | 2 | 2008 | 57 | 0.390 |
Why?
|
| Escin | 1 | 2011 | 2 | 0.390 |
Why?
|
| RNA Interference | 1 | 2020 | 2846 | 0.380 |
Why?
|
| Blotting, Western | 8 | 2015 | 5039 | 0.380 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 110 | 0.370 |
Why?
|
| Down-Regulation | 5 | 2020 | 2918 | 0.370 |
Why?
|
| Airway Remodeling | 1 | 2012 | 134 | 0.360 |
Why?
|
| Pressoreceptors | 1 | 2010 | 100 | 0.360 |
Why?
|
| Dinoprost | 5 | 2003 | 138 | 0.350 |
Why?
|
| Substrate Specificity | 4 | 2017 | 1792 | 0.350 |
Why?
|
| Thorax | 1 | 2013 | 553 | 0.350 |
Why?
|
| Oxytocin | 3 | 2022 | 401 | 0.340 |
Why?
|
| Humans | 74 | 2024 | 760261 | 0.340 |
Why?
|
| Aorta, Thoracic | 8 | 2015 | 1097 | 0.340 |
Why?
|
| Cardiovascular System | 2 | 2015 | 850 | 0.320 |
Why?
|
| Renal Circulation | 2 | 2009 | 292 | 0.320 |
Why?
|
| Lower Extremity | 1 | 2017 | 1196 | 0.320 |
Why?
|
| Male | 57 | 2024 | 359413 | 0.320 |
Why?
|
| Muscles | 1 | 2014 | 1581 | 0.320 |
Why?
|
| Proteinuria | 2 | 2022 | 594 | 0.320 |
Why?
|
| Drug Design | 1 | 2014 | 1062 | 0.310 |
Why?
|
| Splanchnic Circulation | 1 | 2008 | 110 | 0.310 |
Why?
|
| Leukocyte Rolling | 1 | 2008 | 71 | 0.310 |
Why?
|
| Membrane Potentials | 6 | 2011 | 1095 | 0.300 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 132 | 0.300 |
Why?
|
| Mesentery | 1 | 2008 | 203 | 0.300 |
Why?
|
| Developing Countries | 1 | 2020 | 2880 | 0.300 |
Why?
|
| Enzyme Activation | 11 | 2007 | 3604 | 0.290 |
Why?
|
| Potassium Channel Blockers | 3 | 2015 | 161 | 0.290 |
Why?
|
| Abdomen | 1 | 2013 | 1124 | 0.280 |
Why?
|
| Protein Kinase C-alpha | 1 | 2007 | 113 | 0.280 |
Why?
|
| Nitroprusside | 5 | 2012 | 273 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 620 | 0.280 |
Why?
|
| Tissue Distribution | 5 | 2017 | 2262 | 0.280 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 864 | 0.270 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 531 | 0.270 |
Why?
|
| Culture Techniques | 5 | 2004 | 530 | 0.260 |
Why?
|
| Gamma Rays | 1 | 2007 | 317 | 0.260 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 796 | 0.260 |
Why?
|
| Eclampsia | 1 | 2006 | 56 | 0.260 |
Why?
|
| Microcirculation | 2 | 2008 | 1279 | 0.260 |
Why?
|
| Nitrites | 4 | 2013 | 159 | 0.260 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3207 | 0.260 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2010 | 530 | 0.260 |
Why?
|
| Calmodulin | 1 | 2006 | 217 | 0.250 |
Why?
|
| Cytokines | 4 | 2022 | 7345 | 0.250 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2006 | 110 | 0.250 |
Why?
|
| Endothelial Cells | 5 | 2011 | 3537 | 0.240 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1380 | 0.240 |
Why?
|
| Rats, Inbred SHR | 5 | 2003 | 186 | 0.240 |
Why?
|
| Estrus | 2 | 2014 | 70 | 0.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1137 | 0.240 |
Why?
|
| Swine | 10 | 2004 | 5902 | 0.230 |
Why?
|
| Hemodynamics | 2 | 2017 | 4169 | 0.230 |
Why?
|
| Diltiazem | 3 | 2016 | 131 | 0.230 |
Why?
|
| Kidney | 4 | 2009 | 7072 | 0.230 |
Why?
|
| MicroRNAs | 1 | 2020 | 3784 | 0.230 |
Why?
|
| Potassium Channels | 1 | 2007 | 532 | 0.230 |
Why?
|
| Cyclins | 1 | 2006 | 593 | 0.230 |
Why?
|
| Placenta Diseases | 1 | 2006 | 196 | 0.220 |
Why?
|
| Dilatation, Pathologic | 3 | 2013 | 527 | 0.220 |
Why?
|
| Calcium Channels | 3 | 2009 | 619 | 0.220 |
Why?
|
| Aging | 3 | 2009 | 8641 | 0.220 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 579 | 0.220 |
Why?
|
| Cadherins | 1 | 2008 | 898 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2019 | 4896 | 0.220 |
Why?
|
| Osmolar Concentration | 5 | 2012 | 662 | 0.210 |
Why?
|
| Extracellular Space | 2 | 2002 | 565 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 2731 | 0.210 |
Why?
|
| Cells, Cultured | 8 | 2024 | 18968 | 0.210 |
Why?
|
| Metalloproteases | 1 | 2022 | 61 | 0.210 |
Why?
|
| Ferrets | 5 | 1995 | 176 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4409 | 0.200 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1583 | 0.200 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 290 | 0.200 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 68 | 0.200 |
Why?
|
| Aldosterone | 3 | 2011 | 868 | 0.200 |
Why?
|
| Guanylate Cyclase | 2 | 2013 | 205 | 0.200 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 694 | 0.190 |
Why?
|
| RNA, Messenger | 5 | 2022 | 12762 | 0.190 |
Why?
|
| Fura-2 | 5 | 2001 | 107 | 0.190 |
Why?
|
| Monocrotaline | 2 | 2012 | 27 | 0.190 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2004 | 178 | 0.190 |
Why?
|
| Oligopeptides | 3 | 2014 | 1188 | 0.190 |
Why?
|
| Nitrates | 3 | 2013 | 264 | 0.180 |
Why?
|
| Eicosanoids | 2 | 2002 | 278 | 0.180 |
Why?
|
| Connexins | 1 | 2022 | 351 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 2010 | 146 | 0.180 |
Why?
|
| Apoptosis | 3 | 2021 | 9497 | 0.180 |
Why?
|
| Maleimides | 2 | 2016 | 114 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2063 | 0.180 |
Why?
|
| Thrombophlebitis | 2 | 2013 | 289 | 0.180 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2138 | 0.180 |
Why?
|
| Scleroderma, Localized | 2 | 2013 | 87 | 0.170 |
Why?
|
| Muscle Tonus | 3 | 2012 | 82 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 1490 | 0.170 |
Why?
|
| Leukocytes | 1 | 2008 | 2030 | 0.170 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2002 | 291 | 0.170 |
Why?
|
| Sodium | 2 | 2002 | 1601 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2015 | 14396 | 0.170 |
Why?
|
| Models, Animal | 4 | 2010 | 2117 | 0.170 |
Why?
|
| Oxytocics | 1 | 2000 | 65 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2755 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2016 | 8314 | 0.170 |
Why?
|
| Aorta, Abdominal | 2 | 2017 | 622 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2009 | 3107 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 127 | 0.170 |
Why?
|
| Spironolactone | 2 | 2015 | 411 | 0.160 |
Why?
|
| Phenols | 2 | 2015 | 513 | 0.160 |
Why?
|
| Hindlimb | 1 | 2021 | 510 | 0.160 |
Why?
|
| Oxadiazoles | 3 | 2004 | 94 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7854 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2019 | 2671 | 0.150 |
Why?
|
| Trophoblasts | 1 | 2019 | 224 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2009 | 2093 | 0.150 |
Why?
|
| Immunoblotting | 4 | 2008 | 1649 | 0.150 |
Why?
|
| Risk Factors | 10 | 2020 | 74269 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2006 | 2937 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2001 | 641 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 1122 | 0.150 |
Why?
|
| Fertility | 1 | 2022 | 772 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2011 | 364 | 0.150 |
Why?
|
| Gelatinases | 1 | 2017 | 88 | 0.140 |
Why?
|
| Enzyme Activators | 1 | 2017 | 57 | 0.140 |
Why?
|
| Enzyme Precursors | 1 | 2017 | 174 | 0.140 |
Why?
|
| Saphenous Vein | 4 | 2024 | 538 | 0.140 |
Why?
|
| Cysteine | 1 | 2022 | 897 | 0.140 |
Why?
|
| Ion Transport | 3 | 2003 | 318 | 0.140 |
Why?
|
| Rats, Inbred WKY | 4 | 2001 | 151 | 0.140 |
Why?
|
| Hyperhomocysteinemia | 1 | 2017 | 118 | 0.140 |
Why?
|
| Phorbol 12,13-Dibutyrate | 3 | 2001 | 41 | 0.140 |
Why?
|
| rho-Associated Kinases | 2 | 2009 | 281 | 0.140 |
Why?
|
| Gestational Age | 2 | 2017 | 3564 | 0.140 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 929 | 0.140 |
Why?
|
| Mice | 8 | 2020 | 81216 | 0.130 |
Why?
|
| Quinoxalines | 3 | 2004 | 297 | 0.130 |
Why?
|
| Sex Factors | 6 | 2010 | 10530 | 0.130 |
Why?
|
| Myosin Light Chains | 1 | 2016 | 121 | 0.130 |
Why?
|
| Endopeptidases | 1 | 2020 | 772 | 0.130 |
Why?
|
| Tetraethylammonium | 1 | 2015 | 55 | 0.130 |
Why?
|
| Lung | 2 | 2012 | 9989 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 2 | 2017 | 1305 | 0.130 |
Why?
|
| Dimerization | 1 | 2017 | 890 | 0.130 |
Why?
|
| Birth Weight | 2 | 2019 | 2094 | 0.130 |
Why?
|
| Renin-Angiotensin System | 2 | 2015 | 739 | 0.130 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 280 | 0.120 |
Why?
|
| Verapamil | 3 | 2004 | 242 | 0.120 |
Why?
|
| Nitriles | 2 | 2010 | 955 | 0.120 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 657 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 2020 | 455 | 0.120 |
Why?
|
| Protein Transport | 3 | 2007 | 1966 | 0.120 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 101 | 0.120 |
Why?
|
| Viper Venoms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2004 | 819 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2024 | 9283 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4573 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11064 | 0.110 |
Why?
|
| Labor, Obstetric | 1 | 2017 | 321 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 951 | 0.110 |
Why?
|
| Heart Injuries | 1 | 2015 | 208 | 0.110 |
Why?
|
| Mitogens | 1 | 1993 | 230 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1791 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2009 | 478 | 0.110 |
Why?
|
| Hydrostatic Pressure | 1 | 2013 | 95 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 1999 | 1578 | 0.110 |
Why?
|
| Thromboxane-A Synthase | 1 | 2012 | 34 | 0.110 |
Why?
|
| Caffeine | 3 | 2003 | 701 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2015 | 1992 | 0.100 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 165 | 0.100 |
Why?
|
| Leg | 1 | 2017 | 1091 | 0.100 |
Why?
|
| Reference Values | 3 | 2008 | 4920 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2011 | 1697 | 0.100 |
Why?
|
| Indoles | 2 | 2016 | 1830 | 0.100 |
Why?
|
| Ammonium Chloride | 1 | 2012 | 72 | 0.100 |
Why?
|
| Prostaglandins I | 1 | 2011 | 13 | 0.100 |
Why?
|
| Age Factors | 3 | 2020 | 18415 | 0.100 |
Why?
|
| Potassium | 3 | 1993 | 1318 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 107 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2014 | 392 | 0.100 |
Why?
|
| Cholinergic Agonists | 1 | 2012 | 75 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2017 | 983 | 0.100 |
Why?
|
| Fetal Development | 1 | 2017 | 765 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 899 | 0.100 |
Why?
|
| Tyrosine | 2 | 1996 | 1440 | 0.100 |
Why?
|
| Diosmin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 18 | 0.100 |
Why?
|
| Norepinephrine | 3 | 1990 | 900 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 1992 | 924 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 318 | 0.090 |
Why?
|
| Echinomycin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Myography | 1 | 2012 | 111 | 0.090 |
Why?
|
| Sapogenins | 1 | 2010 | 3 | 0.090 |
Why?
|
| Naphthalenes | 2 | 2004 | 198 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 2476 | 0.090 |
Why?
|
| Dermatitis | 1 | 2013 | 200 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2013 | 295 | 0.090 |
Why?
|
| Ginsenosides | 1 | 2010 | 13 | 0.090 |
Why?
|
| Butadienes | 1 | 2010 | 107 | 0.090 |
Why?
|
| Integrins | 1 | 2015 | 840 | 0.090 |
Why?
|
| Physical Stimulation | 1 | 2012 | 518 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 1634 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 600 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2010 | 198 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 555 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2001 | 532 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 141 | 0.090 |
Why?
|
| Gene Expression | 2 | 2021 | 7592 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 412 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 303 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 497 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 152 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2012 | 706 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 17628 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 10340 | 0.080 |
Why?
|
| Renin | 1 | 2011 | 636 | 0.080 |
Why?
|
| Inflammation | 1 | 2009 | 10757 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 2415 | 0.080 |
Why?
|
| Cell Separation | 3 | 2001 | 1720 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 315 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 330 | 0.080 |
Why?
|
| Histone Demethylases | 1 | 2011 | 323 | 0.080 |
Why?
|
| Cytosol | 2 | 2007 | 887 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6775 | 0.080 |
Why?
|
| Orchiectomy | 2 | 2001 | 470 | 0.070 |
Why?
|
| Ovariectomy | 2 | 2001 | 611 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 474 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 1145 | 0.070 |
Why?
|
| Cromakalim | 1 | 2007 | 22 | 0.070 |
Why?
|
| Rabbits | 5 | 2011 | 4773 | 0.070 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2007 | 43 | 0.070 |
Why?
|
| Losartan | 1 | 2009 | 258 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 20 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 16543 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 114 | 0.070 |
Why?
|
| Time Factors | 6 | 2010 | 40133 | 0.070 |
Why?
|
| Ankle Brachial Index | 2 | 2017 | 163 | 0.070 |
Why?
|
| Organ Size | 1 | 2012 | 2249 | 0.070 |
Why?
|
| Sympathetic Fibers, Postganglionic | 1 | 2006 | 14 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2449 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 326 | 0.070 |
Why?
|
| NAD | 1 | 2010 | 610 | 0.070 |
Why?
|
| Protein Kinases | 1 | 1993 | 1612 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2007 | 1167 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 476 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10434 | 0.070 |
Why?
|
| Lymphokines | 1 | 2009 | 929 | 0.070 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 385 | 0.070 |
Why?
|
| Synovial Membrane | 1 | 2009 | 524 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2127 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 435 | 0.070 |
Why?
|
| Aneurysm | 1 | 2009 | 337 | 0.070 |
Why?
|
| Metformin | 1 | 2013 | 912 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 275 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1995 | 2473 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2007 | 1314 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1977 | 0.060 |
Why?
|
| Piperidines | 1 | 2014 | 1650 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 881 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6543 | 0.060 |
Why?
|
| Portal Vein | 3 | 1992 | 429 | 0.060 |
Why?
|
| Ligands | 1 | 2012 | 3277 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2015 | 5429 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 334 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3520 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4286 | 0.060 |
Why?
|
| Vasculitis | 1 | 2009 | 523 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2008 | 768 | 0.060 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 426 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1494 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15273 | 0.060 |
Why?
|
| Immune System | 1 | 2009 | 795 | 0.060 |
Why?
|
| Random Allocation | 1 | 2008 | 2394 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 201 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2012 | 3524 | 0.060 |
Why?
|
| Constriction | 1 | 2003 | 171 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2014 | 1915 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 2940 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 64947 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2009 | 1156 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 3086 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1666 | 0.050 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2002 | 34 | 0.050 |
Why?
|
| Calcium Channel Agonists | 1 | 2002 | 27 | 0.050 |
Why?
|
| Calcium Radioisotopes | 1 | 2002 | 9 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 6661 | 0.050 |
Why?
|
| Imidazoles | 1 | 2009 | 1178 | 0.050 |
Why?
|
| Phorbol Esters | 2 | 2001 | 108 | 0.050 |
Why?
|
| Kidney Medulla | 1 | 2002 | 169 | 0.050 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2002 | 89 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2282 | 0.050 |
Why?
|
| Stimulation, Chemical | 2 | 1999 | 306 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2001 | 74 | 0.050 |
Why?
|
| Wound Healing | 1 | 2013 | 2786 | 0.050 |
Why?
|
| Natriuresis | 1 | 2001 | 105 | 0.050 |
Why?
|
| China | 2 | 2017 | 2340 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14656 | 0.050 |
Why?
|
| Base Sequence | 1 | 2012 | 12447 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 13456 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5206 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3149 | 0.050 |
Why?
|
| Isotonic Solutions | 1 | 2001 | 116 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5640 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9468 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2001 | 141 | 0.040 |
Why?
|
| Culture Media | 1 | 2002 | 899 | 0.040 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 1991 | 56 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 673 | 0.040 |
Why?
|
| Castration | 1 | 2000 | 153 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2415 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 214 | 0.040 |
Why?
|
| Monocytes | 1 | 2009 | 2574 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3811 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2000 | 157 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1633 | 0.040 |
Why?
|
| Carbazoles | 1 | 2001 | 221 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 65 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 338 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2235 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2852 | 0.040 |
Why?
|
| Biological Transport | 2 | 1994 | 2087 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 242 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2009 | 2522 | 0.040 |
Why?
|
| Isoquinolines | 2 | 1991 | 353 | 0.040 |
Why?
|
| Postmenopause | 1 | 2007 | 2503 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2003 | 882 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1617 | 0.040 |
Why?
|
| Carcinogens | 1 | 2000 | 449 | 0.040 |
Why?
|
| Diet | 2 | 2008 | 8008 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2001 | 543 | 0.040 |
Why?
|
| Obesity | 1 | 1999 | 12915 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22041 | 0.040 |
Why?
|
| Perfusion | 1 | 2002 | 1376 | 0.040 |
Why?
|
| Arginine | 1 | 2001 | 934 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2874 | 0.040 |
Why?
|
| Body Weight | 1 | 2008 | 4613 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 1246 | 0.030 |
Why?
|
| Pyridines | 1 | 2009 | 2877 | 0.030 |
Why?
|
| Genotype | 1 | 2011 | 12959 | 0.030 |
Why?
|
| Myocardium | 1 | 2009 | 4688 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 1075 | 0.030 |
Why?
|
| Serotonin | 1 | 2001 | 1041 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2004 | 4044 | 0.030 |
Why?
|
| Vitamin D | 1 | 2009 | 3293 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 1882 | 0.030 |
Why?
|
| Middle Aged | 5 | 2024 | 220175 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4358 | 0.030 |
Why?
|
| Differential Threshold | 1 | 1994 | 80 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 456 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3598 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 1996 | 8945 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 640 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 1993 | 82 | 0.030 |
Why?
|
| Mammals | 1 | 1998 | 1129 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 1914 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 13311 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 219847 | 0.030 |
Why?
|
| Sarcolemma | 1 | 1991 | 65 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 26168 | 0.020 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1991 | 385 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3466 | 0.020 |
Why?
|
| Aged | 4 | 2024 | 168995 | 0.020 |
Why?
|
| Prevalence | 2 | 2017 | 15687 | 0.020 |
Why?
|
| Microscopy | 1 | 1995 | 881 | 0.020 |
Why?
|
| Piperazines | 2 | 1991 | 2520 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1987 | 163 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17766 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9712 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12156 | 0.010 |
Why?
|
| Rats, Inbred Dahl | 1 | 2002 | 34 | 0.010 |
Why?
|
| Ion Channels | 1 | 1987 | 1043 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 193 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4264 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 514 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1990 | 87 | 0.010 |
Why?
|
| Thionucleotides | 2 | 1990 | 112 | 0.010 |
Why?
|
| Guanosine Triphosphate | 2 | 1990 | 316 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 13629 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1987 | 2825 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 24086 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2002 | 2178 | 0.010 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 1992 | 100 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 4169 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1990 | 169 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1990 | 287 | 0.010 |
Why?
|
| Buffers | 1 | 1989 | 144 | 0.010 |
Why?
|
| Methods | 1 | 1989 | 1075 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 4462 | 0.000 |
Why?
|
| Permeability | 1 | 1989 | 719 | 0.000 |
Why?
|
| GTP-Binding Proteins | 1 | 1989 | 951 | 0.000 |
Why?
|